Elesclomol (STA-4783)

Name: Elesclomol (STA-4783)
Brand: Selleck Chemicals
SKU: S1052
Rating: 5 (10 reviews)

For research use only.

Catalog No.S1052

10 publications

Elesclomol (STA-4783) Chemical Structure

CAS No. 488832-69-5

Elesclomol (STA-4783) is a novel potent oxidative stress inducer that elicits pro-apoptosis events among tumor cells. Phase 3.

Selleck's Elesclomol (STA-4783) has been cited by 10 publications

Cell, 2017, 168(1-2):86-100

PubMed: 27916275 ( click the link to review the publication )

Nat Commun, 2020, 15;11(1):2423

PubMed: 32415069 ( click the link to review the publication )

EBioMedicine, 2020, 54:102715

PubMed: 32251998 ( click the link to review the publication )

Cancers (Basel), 2020, 12(6):E1645

PubMed: 32575908 ( click the link to review the publication )

Osteoporos Int, 2018, 29(8):1917-1926

PubMed: 29860665 ( click the link to review the publication )

Oncol Rep, 2018, 40(2):635-646

PubMed: 29917168 ( click the link to review the publication )

Int J Biochem Cell Biol, 2017, 85:166-174

PubMed: 28259749 ( click the link to review the publication )

Int J Radiat Biol, 2017, 93(2):194-203

PubMed: 27600766 ( click the link to review the publication )

Oncotarget, 2016, 10.18632/oncotarget.10921

PubMed: 27486766 ( click the link to review the publication )

BMC Genomics, 2014, 15(1):263

PubMed: 24708151 ( click the link to review the publication )

4 Customer Reviews

BMC Genomics 2014 15(1), 263. Elesclomol (STA-4783) purchased from Selleck.

Treatment with elesclomol inhibits cancer cell growth and induces apoptosis by increasing ROS levels. a. Cell growth of SMOV2, IGROV1, and OVCA432 ovarian cancer cells treated with elesclomol in the presence or absence of the antioxidant NAC for 72 h. Cell growth was measured using the WST-1 assay and quantified relative to DMSO treated controls.

Oncotarget, 2016, 7(35):56933-56943. Elesclomol (STA-4783) purchased from Selleck.
Overexpression of GILZ favors oxidative cell death Dose-response of ROS production (HE staining) (A) or cell death (PI staining) (B) in indicated cells exposed toincreasing concentrations of elesclomol for 24 h (mean ± SD, n = 3, *p < 0.05). Alternatively, cells were treated with elesclomol for 24 h with or without pre-incubation with10 mM N-Acetyl Cysteine (NAC) for 12 h before HE staining (A) or PI staining (B) (mean ± SD, n = 3, *p < 0.05).

Int J Biochem Cell Biol, 2017, 85:166-174. Elesclomol (STA-4783) purchased from Selleck.

The proliferation of PC3 and LNCaP cells exposed to elesclomol at a range of concentrations for 48 h was assessed using MTT assay. Results are expressed as percentage of MTT absorbance of untreated cells at 0 h. p < .05 and p < .01 compared to untreated controls. Data are means ± SEM; n = 4.

Int J Radiat Biol, 2017, 93(2):194-203. Elesclomol (STA-4783) purchased from Selleck.

Purity & Quality Control

Choose Selective HSP (HSP90) Inhibitors

Biological Activity

Description

Elesclomol (STA-4783) is a novel potent oxidative stress inducer that elicits pro-apoptosis events among tumor cells. Phase 3.

Targets

HSP70 ^[1]
(Cell-free assay)

In vitro

Elesclomol significantly induces the expression of heat shock stress response genes and metallothionein genes, a signature transcription profile indicative of oxidative stress in Hs294T cells. Elesclomol (100 nM) rapidly induces Hsp70 RNA levels with a 4.8-fold increase at 1 hour and a 160-fold increase at 6 hours in Ramos Burkitt's lymphoma B cells in consistent with the intracellular ROS content which increases by 20% as early as 0.5 hour and 385% at 6 hours, and the induction of Hsp70 can be blocked by antioxidants N-acetylcysteine (NAC) and Tiron pretreatment. Elesclomol increases the number of early and late apoptotic cells with 3.7- and 11-fold through the induction of oxidative stress, which can be completely blocked by NAC, while having little effect on normal cells. ^[1] Elesclomol significantly inhibits the cell viability of SK-MEL-5, MCF-7, and HL-60 with IC50 of 110 nM, 24 nM and 9 nM, respectively. ^[2] Elesclomol induces copper-dependent ROS generation and cytoxicity in yeast. Instead of working through a specific cellular protein target, Elesclomol interacts with the electron transport chain (ETC), a biologically coherent set of processes occurring in the mitochondrion, to generate high levels of ROS within the organelle and consequently cell death. ^[3]

Cell Data

Cell Lines	Assay Type	Activity Description	PMID
NOS-1 cell	MUTHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	M3HqR2lvcGmkaYTpc44hd2ZiaIXtZY4hVk:VLUGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhOy54NnWtNFUh\|ryP	M1jIZXNCVkeHUh?=
CAL-51 cell	M{S0WWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7	NX;Ec\|NUUW6qaXLpeIlwdiCxZjDoeY1idiCFQVytOVEh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0xNjF{NjDuUS=>	MVPTRW5ITVJ?
ABC-1 cell	MXrHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	M1fLRmlvcGmkaYTpc44hd2ZiaIXtZY4hSUKFLUGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlM3PSCwTR?=	MXnTRW5ITVJ?
A2780 cell	NVK3[pdMT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	M1jHTGlvcGmkaYTpc44hd2ZiaIXtZY4hSTJ5OECgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlU6PCCwTR?=	MYTTRW5ITVJ?
ES1 cell	MYDHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	MmHaTY5pcWKrdHnvckBw\iCqdX3hckBGWzFiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1yLke0PUBvVQ>?	M{[5XnNCVkeHUh?=
HUTU-80 cell	NX2zSVRzT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	NUnG[pFzUW6qaXLpeIlwdiCxZjDoeY1idiCKVWTVMVgxKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OC55OUGgcm0>	Mn\GV2FPT0WU
NCI-H292 cell	NFTIdo9Iem:5dHigbY5pcWKrdHnvckBie3OjeR?=	MWPJcohq[mm2aX;uJI9nKGi3bXHuJG5EUS2KMkmyJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE45QDZibl2=	MY\TRW5ITVJ?
NB69 cell	NEXze2ZIem:5dHigbY5pcWKrdHnvckBie3OjeR?=	MmTQTY5pcWKrdHnvckBw\iCqdX3hckBPSjZ7IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTB;MT6yNkBvVQ>?	M{i5S3NCVkeHUh?=
ES8 cell	MWDHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	M4jO[2lvcGmkaYTpc44hd2ZiaIXtZY4hTVN6IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTB;MT6zNkBvVQ>?	MX;TRW5ITVJ?
BCPAP cell	MUjHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	MVzJcohq[mm2aX;uJI9nKGi3bXHuJGJEWEGSIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTB;MT6zOEBvVQ>?	MkLHV2FPT0WU
T-24 cell	MmnsS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	NG\FO4NKdmirYnn0bY9vKG:oIHj1cYFvKFRvMkSgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xMlU2KG6P	MXPTRW5ITVJ?
EW-16 cell	MmLnS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	MlXKTY5pcWKrdHnvckBw\iCqdX3hckBGXy1zNjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUGuOlEhdk1?	NXTrRYtRW0GQR1XS
OVCAR-5 cell	M{\LcGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7	NUnOfYZ5UW6qaXLpeIlwdiCxZjDoeY1idiCRVlPBVk02KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OS56MzDuUS=>	NH\Zc3hUSU6JRWK=
SF126 cell	MoPsS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	Mn;PTY5pcWKrdHnvckBw\iCqdX3hckBUTjF{NjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUGuPVUhdk1?	M1nvcHNCVkeHUh?=
KP-4 cell	NVHhZoh{T3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	Mn7oTY5pcWKrdHnvckBw\iCqdX3hckBMWC12IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTB;Mj6xO{BvVQ>?	MmHuV2FPT0WU
GAMG cell	MmDQS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	MXTJcohq[mm2aX;uJI9nKGi3bXHuJGdCVUdiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1{LkWxJI5O	M4LqVXNCVkeHUh?=
HOS cell	NWXqdW5uT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	M{[yOWlvcGmkaYTpc44hd2ZiaIXtZY4hUE:VIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTB;Mj61N{BvVQ>?	M1Hn[nNCVkeHUh?=
CHL-1 cell	NI[5eo5Iem:5dHigbY5pcWKrdHnvckBie3OjeR?=	NVe0XYZTUW6qaXLpeIlwdiCxZjDoeY1idiCFSFytNUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVIvQDFibl2=	NF;TdGZUSU6JRWK=
AGS cell	M3TmNGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7	MX;Jcohq[mm2aX;uJI9nKGi3bXHuJGFIWyClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR\|UxRTJwOE[gcm0>	M4O4R3NCVkeHUh?=
MDA-MB-157 cell	NF75VIxIem:5dHigbY5pcWKrdHnvckBie3OjeR?=	MlHKTY5pcWKrdHnvckBw\iCqdX3hckBOTEFvTVKtNVU4KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:Oi57MjDuUS=>	NXLab3o3W0GQR1XS
HSC-3 cell	NH;qSZFIem:5dHigbY5pcWKrdHnvckBie3OjeR?=	M{fVeWlvcGmkaYTpc44hd2ZiaIXtZY4hUFOFLUOgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2zMlAzKG6P	M1O5Z3NCVkeHUh?=
CAL-72 cell	NUTVWXQzT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	M{jMdWlvcGmkaYTpc44hd2ZiaIXtZY4hS0GOLUeyJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9N{4xOiCwTR?=	NWjUWGF5W0GQR1XS
NBsusSR cell	M1jCNWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7	MYLJcohq[mm2aX;uJI9nKGi3bXHuJG5De3W\|U2KgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2zMlE{KG6P	NGC5emNUSU6JRWK=
ES7 cell	M2nRdWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7	MlnoTY5pcWKrdHnvckBw\iCqdX3hckBGWzdiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1\|LkW5JI5O	MX7TRW5ITVJ?
H-EMC-SS cell	NH;6SHdIem:5dHigbY5pcWKrdHnvckBie3OjeR?=	M3XhTmlvcGmkaYTpc44hd2ZiaIXtZY4hUC2HTVOtV3Mh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0{NjZ6IH7N	MUXTRW5ITVJ?
NCI-H1703 cell	NG\EZWRIem:5dHigbY5pcWKrdHnvckBie3OjeR?=	MYHJcohq[mm2aX;uJI9nKGi3bXHuJG5EUS2KMUewN{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVMvPjhibl2=	NVvGbVRjW0GQR1XS
BHT-101 cell	MWnHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	Mk\kTY5pcWKrdHnvckBw\iCqdX3hckBDUFRvMUCxJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9N{44OiCwTR?=	NHHQ[WhUSU6JRWK=
SK-OV-3 cell	MVzHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	M4fxOWlvcGmkaYTpc44hd2ZiaIXtZY4hW0tvT2[tN{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVMvPzVibl2=	MkjZV2FPT0WU
EW-24 cell	NFj5S4hIem:5dHigbY5pcWKrdHnvckBie3OjeR?=	MnvXTY5pcWKrdHnvckBw\iCqdX3hckBGXy1{NDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUOuPFMhdk1?	MXfTRW5ITVJ?
PSN1 cell	MVXHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	MXPJcohq[mm2aX;uJI9nKGi3bXHuJHBUVjFiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1\|Lki0JI5O	M17DRXNCVkeHUh?=
OVCAR-8 cell	NFP6cXVIem:5dHigbY5pcWKrdHnvckBie3OjeR?=	MWDJcohq[mm2aX;uJI9nKGi3bXHuJG9XS0GULUigZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2zMlk6KG6P	MVvTRW5ITVJ?
NCI-H1563 cell	M4j3[Wdzd3e2aDDpcohq[mm2aX;uJIF{e2G7	Mn;5TY5pcWKrdHnvckBw\iCqdX3hckBPS0lvSEG1OlMh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF01NjF\|IH7N	NUfJTJFHW0GQR1XS
SW756 cell	MWfHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	NH\SUlBKdmirYnn0bY9vKG:oIHj1cYFvKFOZN{W2JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OE4yOyCwTR?=	NH7Uc3dUSU6JRWK=
A375 cell	NVTFdoVZT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	M33ie2lvcGmkaYTpc44hd2ZiaIXtZY4hSTN5NTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUSuNVQhdk1?	NUfRWnFsW0GQR1XS
Ca9-22 cell	MYnHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	NHfZVG5KdmirYnn0bY9vKG:oIHj1cYFvKEOjOT2yNkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVQvOjVibl2=	MXLTRW5ITVJ?
SW1990 cell	NInoRm9Iem:5dHigbY5pcWKrdHnvckBie3OjeR?=	NF7MNppKdmirYnn0bY9vKG:oIHj1cYFvKFOZMUm5NEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVQvOzJibl2=	MnvFV2FPT0WU
ES4 cell	MVjHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	NVXGdIpKUW6qaXLpeIlwdiCxZjDoeY1idiCHU{SgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME20MlM6KG6P	M1zoNHNCVkeHUh?=
HCE-T cell	MYPHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	M3L0dWlvcGmkaYTpc44hd2ZiaIXtZY4hUEOHLWSgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME20MlQ2KG6P	MVHTRW5ITVJ?
MOLT-16 cell	MmjBS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	NXLGOoV6UW6qaXLpeIlwdiCxZjDoeY1idiCPT1zUMVE3KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:PC53MzDuUS=>	MlLWV2FPT0WU
HSC-4 cell	NFe2RW5Iem:5dHigbY5pcWKrdHnvckBie3OjeR?=	NV3xe\|I2UW6qaXLpeIlwdiCxZjDoeY1idiCKU1OtOEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVQvQCCwTR?=	NGDDSlVUSU6JRWK=
NCI-SNU-1 cell	MoXvS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	NGX2OHlKdmirYnn0bY9vKG:oIHj1cYFvKE6FST3TUnUuOSClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR\|UxRTRwOE[gcm0>	NWHOV3EzW0GQR1XS
EW-11 cell	MX\Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	MWPJcohq[mm2aX;uJI9nKGi3bXHuJGVYNTFzIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTB;ND65JI5O	MWHTRW5ITVJ?
HT-1080 cell	NGHpW2xIem:5dHigbY5pcWKrdHnvckBie3OjeR?=	MoLtTY5pcWKrdHnvckBw\iCqdX3hckBJXC1zMEiwJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OE46QSCwTR?=	MnvKV2FPT0WU
MES-SA/Dx5 cells	NXTxcIw6S3m2b4TvfIlkcXS7IHHzd4F6	NVPOWHVbS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hVUWVLWPBM2R5PSClZXzsd{whUUN3ME21JI5O	MlfoNlM6Ozd7OEG=
SW1710 cell	NWDmVo01T3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	NVrxd\|VKUW6qaXLpeIlwdiCxZjDoeY1idiCVV{G3NVAh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF02NjF4IH7N	MVrTRW5ITVJ?
EW-1 cell	M1LzXWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7	NGLPWVBKdmirYnn0bY9vKG:oIHj1cYFvKEWZLUGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME21MlI1KG6P	M2e0RXNCVkeHUh?=
BV-173 cell	NHO2VIlIem:5dHigbY5pcWKrdHnvckBie3OjeR?=	M2LaV2lvcGmkaYTpc44hd2ZiaIXtZY4hSlZvMUezJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OU4{QSCwTR?=	MkjKV2FPT0WU
TE-8 cell	MnLqS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	MmezTY5pcWKrdHnvckBw\iCqdX3hckBVTS16IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTB;NT60NUBvVQ>?	NHjaZZBUSU6JRWK=
G-401 cell	NWDYcnhqT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	NXvJRWE5UW6qaXLpeIlwdiCxZjDoeY1idiCJLUSwNUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVUvPDNibl2=	M4K2d3NCVkeHUh?=
KOSC-2 cell	MXPHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	MW\Jcohq[mm2aX;uJI9nKGi3bXHuJGtQW0NvMjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUWuOFUhdk1?	NVvvcohtW0GQR1XS
HuCCT1 cell	NY\s[HRWT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	MlrYTY5pcWKrdHnvckBw\iCqdX3hckBJfUOFVEGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME21MlUzKG6P	NHix[Y9USU6JRWK=
FADU cell	MVfHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	NFjZW4lKdmirYnn0bY9vKG:oIHj1cYFvKE[DRGWgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME21MlY3KG6P	M4jiRnNCVkeHUh?=
MHH-ES-1 cell	NXXoZ2c6T3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	NFKwPJNKdmirYnn0bY9vKG:oIHj1cYFvKE2KSD3FV{0yKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:PS54OTDuUS=>	M3X1U3NCVkeHUh?=
ES3 cell	MnfmS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	MYfJcohq[mm2aX;uJI9nKGi3bXHuJGVUOyClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR\|UxRTVwN{mgcm0>	MlfzV2FPT0WU
OVCAR-4 cell	MnXHS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	NXGzSJZ{UW6qaXLpeIlwdiCxZjDoeY1idiCRVlPBVk01KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:PS56NzDuUS=>	M3f1eHNCVkeHUh?=
HD-MY-Z cell	MlfaS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	Moj4TY5pcWKrdHnvckBw\iCqdX3hckBJTC2PWT3aJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OU46OSCwTR?=	MWjTRW5ITVJ?
human JAR cell	M4e5Wmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7	NWHUOJo6UW6qaXLpeIlwdiCxZjDoeY1idiCMQWKgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME21Mlk4KG6P	NVTHN4ZLW0GQR1XS
A427 cell	NFjT[XFIem:5dHigbY5pcWKrdHnvckBie3OjeR?=	MnvkTY5pcWKrdHnvckBw\iCqdX3hckBCPDJ5IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTB;Nj6wO{BvVQ>?	NF:xe5RUSU6JRWK=
697 cell	MVjHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	MVnJcohq[mm2aX;uJI9nKGi3bXHuJFY6PyClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR\|UxRTZwMUOgcm0>	M{HBPXNCVkeHUh?=
OVCAR-3 cell	NXfJbo1kT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	M1\LcGlvcGmkaYTpc44hd2ZiaIXtZY4hV1[FQWKtN{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVYvOiCwTR?=	M4jNcXNCVkeHUh?=
human NB14 cell	MmHlS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	MWnJcohq[mm2aX;uJI9nKGi3bXHuJG5DOTRiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD14Lk[0JI5O	MonDV2FPT0WU
GB-1 cell	M3zSOGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7	NEe4W\|lKdmirYnn0bY9vKG:oIHj1cYFvKEeELUGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME22MlcyKG6P	NWrZeIl[W0GQR1XS
COR-L105 cell	NGLsTnhIem:5dHigbY5pcWKrdHnvckBie3OjeR?=	MnLLTY5pcWKrdHnvckBw\iCqdX3hckBEV1JvTEGwOUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVYvPzZibl2=	NHzMT4VUSU6JRWK=
647-V cell	NHrPS3RIem:5dHigbY5pcWKrdHnvckBie3OjeR?=	MYHJcohq[mm2aX;uJI9nKGi3bXHuJFY1Py2YIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTB;Nj65JI5O	NGLjT2RUSU6JRWK=
human K5 cell	NF\JXmtIem:5dHigbY5pcWKrdHnvckBie3OjeR?=	MlPvTY5pcWKrdHnvckBw\iCqdX3hckBMPSClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR\|UxRTdibl2=	Mn7zV2FPT0WU
DMS-273 cell	MmLGS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	M{LLU2lvcGmkaYTpc44hd2ZiaIXtZY4hTE2VLUK3N{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVcvODZibl2=	MoLrV2FPT0WU
UM-UC-3 cell	NYXGc3poT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	M33tbGlvcGmkaYTpc44hd2ZiaIXtZY4hXU1vVVOtN{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVcvODZibl2=	NFrlWVJUSU6JRWK=
HEL cell	NH3kZXBIem:5dHigbY5pcWKrdHnvckBie3OjeR?=	NFrKV2lKdmirYnn0bY9vKG:oIHj1cYFvKEiHTDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUeuNFghdk1?	Ml\YV2FPT0WU
human KU-19-19 cell	MkD5S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	NX;uUo9UUW6qaXLpeIlwdiCxZjDoeY1idiCNVT2xPU0yQSClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR\|UxRTdwMEmgcm0>	M3n5ZnNCVkeHUh?=
MC-IXC cell	MWfHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	NHnzXHNKdmirYnn0bY9vKG:oIHj1cYFvKE2FLVnYR{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVcvOTdibl2=	M2XhU3NCVkeHUh?=
human H4 cell	NIG2XZVIem:5dHigbY5pcWKrdHnvckBie3OjeR?=	M2HHSWlvcGmkaYTpc44hd2ZiaIXtZY4hUDRiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD15LkK1JI5O	NEjHdIhUSU6JRWK=
NUGC-3 cell	NX7EdI53T3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	NFP1V3dKdmirYnn0bY9vKG:oIHj1cYFvKE6XR1OtN{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVcvOzNibl2=	NGD3XZRUSU6JRWK=
CHP-212 cell	NGnRc\|JIem:5dHigbY5pcWKrdHnvckBie3OjeR?=	MV3Jcohq[mm2aX;uJI9nKGi3bXHuJGNJWC1{MUKgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME23MlM1KG6P	MYnTRW5ITVJ?
human SW982 cell	NWHaUVF4T3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	MYPJcohq[mm2aX;uJI9nKGi3bXHuJHNYQTh{IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTB;Nz60OEBvVQ>?	MXHTRW5ITVJ?
C-33-A cell	MYjHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	NV\G[2psUW6qaXLpeIlwdiCxZjDoeY1idiCFLUOzMWEh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF04NjV6IH7N	NXjqO4RsW0GQR1XS
PC-3 cell	MnPQS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	NVK3OoVEUW6qaXLpeIlwdiCxZjDoeY1idiCSQz2zJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9O{45QSCwTR?=	NEX6VZlUSU6JRWK=
COLO-684 cell	NVjrd\|R[T3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	MUfJcohq[mm2aX;uJI9nKGi3bXHuJGNQVE9vNki0JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9PU4zOSCwTR?=	NVz3TG1[W0GQR1XS
SNU-387 cell	MVnHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	M{P5NWlvcGmkaYTpc44hd2ZiaIXtZY4hW06XLUO4O{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVkvPDlibl2=	NITYR2JUSU6JRWK=
U251 cell	MYDHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	NFG3[GJKdmirYnn0bY9vKG:oIHj1cYFvKFV{NUGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME25Mlg3KG6P	MnPWV2FPT0WU
A673 cell	M{ThW2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7	M1i2U2lvcGmkaYTpc44hd2ZiaIXtZY4hSTZ5MzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUGxMlYhdk1?	MWLTRW5ITVJ?
human T47D cell	NV36OFl7T3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	MYLJcohq[mm2aX;uJI9nKGi3bXHuJHQ1P0RiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1zNj63PUBvVQ>?	M3TLc3NCVkeHUh?=
A549 cell	M4LlTmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7	NHraOlZKdmirYnn0bY9vKG:oIHj1cYFvKEF3NEmgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xPU43KG6P	MoD0V2FPT0WU
PC-14 cell	MX7Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	M4\yOWlvcGmkaYTpc44hd2ZiaIXtZY4hWENvMUSgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2yOE44OyCwTR?=	M1zCcnNCVkeHUh?=
A704 cell	NIrrfnFIem:5dHigbY5pcWKrdHnvckBie3OjeR?=	MoLMTY5pcWKrdHnvckBw\iCqdX3hckBCPzB2IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTB;MkeuOFUhdk1?	M{K2N3NCVkeHUh?=
MCF7 cell	M3vlZWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7	NUf4PJE3UW6qaXLpeIlwdiCxZjDoeY1idiCPQ1[3JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9N\|EvOzZibl2=	MomzV2FPT0WU
PC3 cells	MnTrSpVv[3Srb36gZZN{[Xl?	NV[0TmRGUW6qaXLpeIlwdiCxZjDQSGsyNW2nZHnheIVlKEGNVDDwbI9{eGixconsZZRqd25iYYSgWIhzOzB6IILld4llfWViaX6gbJVu[W5iUFOzJINmdGy\|IHL5JGVNUVODLDDJR\|UxRTBwMUGzJO69VQ>?	M1HrWVIyOzRzNke1
F-36P cells	M3PGUnBzd2yrZnXyZZRqd25iYYPzZZk>	NV3RXXpWSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDGMVM3WCClZXzsd{whUUN3ME2wMlI5KM7:TR?=	NGLhbFAzOTN2MU[3OS=>
OCI-AML2 cells	M4DuXHBzd2yrZnXyZZRqd25iYYPzZZk>	MW\BcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKE:FST3BUWwzKGOnbHzzMEBKSzVyPUCuN\|Uh\|ryP	MXWyNVM1OTZ5NR?=
K562 cells	MVvQdo9tcW[ncnH0bY9vKGG\|c3H5	MXTBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEt3NkKgZ4VtdHNuIFnDOVA:OThizszN	MVOyNVM1OTZ5NR?=

... Click to View More Cell Line Experimental Data

In vivo

Although Elesclomol (25-100 mg/kg) as a single agent shows no antitumor activity in nude mouse xenograft models of human breast cancers (MDA435, MCF7 and ZR-75-1), lung cancer (RER) or lymphoma (U937), Elesclomol substantially enhances the efficacy of chemotherapeutic agents such as paclitaxel in these models, both in terms of tumor regression and extended survival of mice. ^[4]

Protocol

Cell Research:^[1]

- Collapse

Cell lines: Hs294T, HSB2, and Ramos
Concentrations: Dissolved in DMSO at a concentration of 10 mM, final concentrations ~500 nM
Incubation Time: 18, or 24 hours
Method: Cells are treated with various concentrations of Elesclomol for 18 or 24 hours. The level of intracellular ROS is monitored using the DCFDA probe, which emits a green fluorescence on oxidation. Cell death is determined by flow cytometry of cells double stained with Annexin V/FITC and propidium iodide (PI) using a Vybrant Apoptosis assay kit.
(Only for Reference)

Animal Research:^[4]

- Collapse

Animal Models: Female CD-1 nude mice bearing established MDA435 breast cancer xenograft tumors
Dosages: ~100 mg/kg
Administration: Intravenous injection
(Only for Reference)

References

[4] Gehrmann M. Curr Opin Investig Drugs, 2006, 7(6), 574-580.

- Collapse

Solubility (25°C)

In vitro	DMSO	80 mg/mL (199.75 mM)
	Water	Insoluble
	Ethanol	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 5% DMSO+40%PEG300+5%Tween80 +50%H2O For best results, use promptly after mixing.	10mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Elesclomol (STA-4783) SDF

Molecular Weight	400.5
Formula	C₁₉H₂₀N₄O₂S₂
CAS No.	488832-69-5
Storage	3 years-20°C powder 2 years-80°C in solvent
Synonyms	N/A
Smiles	CN(C(=S)C1=CC=CC=C1)NC(=O)CC(=O)NN(C)C(=S)C2=CC=CC=C2

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage

mg/kg

Average weight of animals

Dosing volume per animal

Number of animals

Step 2: Enter the in vivo formulation (Different batches have different solubility ratios, please contact Selleck to provide you with the correct ratio)

% DMSO+ % + % Tween 80+ % ddH₂O

Calculate Reset

Calculation results:

Working concentration： mg/ml；

Method for preparing DMSO master liquid: ： mg drug pre-dissolved in μL DMSO (Master liquid concentration mg/mL， Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation：Take μL DMSO master liquid, next addμL PEG300， mix and clarify, next addμL Tween 80，mix and clarify, next add μL ddH₂O，mix and clarify.

Note：1.Please make sure the liquid is clear before adding the next solvent.
2.Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
How can we use the compound for in vivo mouse studies?
Answer:
S1052 in 1% DMSO+30% polyethylene glycol+1% Tween 80 is a suspension, it is fine for oral administration. You can also dissolve S1052 in 0.5-1% CMC-Na solution and treat the mice by oral gavage.

HSP (HSP90) Signaling Pathway Map

Related HSP (HSP90) Products

PU-H71 ^New

PU-H71 (NSC 750424) is a potent and selective inhibitor of HSP90 with IC50 of 51 nM. Phase 1.
KNK437 ^New

KNK437 is a pan-HSP inhibitor, which inhibits the synthesis of inducible HSPs, including HSP105, HSP72, and HSP40.
VER155008 ^New

VER155008 (C07) is a potent Hsp70 family inhibitor with IC50 of 0.5 μM, 2.6 μM, and 2.6 μM in cell-free assays for HSP70, HSC70, and GRP78, respectively, >100-fold selectivity over HSP90. VER155008 inhibits autophagy and causes reduced levels of HSP90 client proteins.
Tanespimycin (17-AAG)

Tanespimycin (17-AAG, CP127374, NSC-330507, KOS 953) is a potent HSP90 inhibitor with IC50 of 5 nM in a cell-free assay, having a 100-fold higher binding affinity for HSP90 derived from tumour cells than HSP90 from normal cells. Tanespimycin (17-AAG) induces apoptosis, necrosis, autophagy and mitophagy. Phase 3.

Features:Displays very low toxicity toward normal cells.
Luminespib (NVP-AUY922)

Luminespib (AUY-922, NVP-AUY922) is a highly potent HSP90 inhibitor for HSP90α/β with IC50 of 13 nM /21 nM in cell-free assays, weaker potency against the HSP90 family members GRP94 and TRAP-1, exhibits the tightest binding of any small-molecule HSP90 ligand. Luminespib (AUY-922, NVP-AUY922) effectively downregulates and destabilizes the IGF-1Rβ protein and results in growth inhibition, autophagy and apoptosis. Phase 2.
Ganetespib (STA-9090)

Ganetespib (STA-9090) is an HSP90 inhibitor with IC50 of 4 nM in OSA 8 cells, induces apoptosis of OSA cells while normal osteoblasts are not affected; active metabolite of STA-1474. Phase 3.
Alvespimycin (17-DMAG) HCl

Alvespimycin (17-DMAG, NSC 707545, BMS 826476, KOS 1022) HCl is a potent HSP90 inhibitor with IC50 of 62 nM in a cell-free assay. Phase 2.

Features:A synthetic derivative Geldanamycin, with lower hepatotoxicity than parent antibiotic & higher potency and bioavailability than the similar derivative 17-AAG.
Geldanamycin

Geldanamycin (NSC 122750) is a natural existing HSP90 inhibitor with K_d of 1.2 μM, specifically disrupts glucocorticoid receptor (GR)/HSP association. Geldanamycin attenuates virus infection-induced ALI (acute lung injury)/ARDS (acute respiratory distress syndrome) by reducing the host's inflammatory responses.
HSP990 (NVP-HSP990)

HSP990 (NVP-HSP990) is a novel, potent and selective HSP90 inhibitor for HSP90α/β with IC50 of 0.6 nM/0.8 nM. NVP-HSP990 induces cell cycle arrest and apoptosis.

Features:NVP-HSP990 is an orally available HSP90 inhibitor and is structurally distinct from other clinical HSP90 inhibitors.
Onalespib (AT13387)

Onalespib (AT13387) is a selective potent Hsp90 inhibitor with IC50 of 18 nM in A375 cells, displays a long duration of anti-tumor activity. Phase 2.

Choose Your Country or Region

By Signaling Pathways

By product type

Elesclomol (STA-4783)